- Investopedia•44 minutes ago
Ocrevus is expected to be a blockbuster drug for Roche, as the company faces generics challenge for its older, established cancer drugs
- Market Realist•44 minutes ago
By the end of 2016, the number of Cosentyx’s new-to-brand prescriptions in the US for PsA and AS indications were higher than those of Amgen’s Enbrel, Johnson & Johnson’s Stelara, and AbbVie’s Humira.
- Market Realist•2 hours ago
Launched in the US in 1Q15, Novartis’s (NVS) Cosentyx managed to report revenues of around $1,128 million in 2016.
NVS : Summary for Novartis AG - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||74.86 - 75.00|
|52 Week Range||66.93 - 83.58|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||26.76|
|Dividend & Yield||2.75 (3.66%)|
|1y Target Est||N/A|